CATX – perspective therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.
Perspective Therapeutics to Participate in Upcoming December Conferences
Form SCHEDULE 13G/A Perspective Therapeutics Filed by: FMR LLC
Form 8-K Perspective Therapeutics For: Dec 01
Form 4 Perspective Therapeutics For: Nov 13 Filed by: Hunt Jonathan Robert
Form 4 Perspective Therapeutics For: Nov 12 Filed by: Williamson Robert F III
Form 10-Q Perspective Therapeutics For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.